Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma Document date: 2018_8_30
ID: uzge50xu_37
Snippet: Study limitations included: 1) the open-label design, which could have affected results through the placebo effect; 2) measurements for both secondary outcomes (i.e., sEDN level and rescue medication usage) were done only 2 times, once at the beginning of the study for baseline and a second time at the end of the study, so it may have been more beneficial to measure serially; 3) patient recruitment was through a few different healthcare centers, .....
Document: Study limitations included: 1) the open-label design, which could have affected results through the placebo effect; 2) measurements for both secondary outcomes (i.e., sEDN level and rescue medication usage) were done only 2 times, once at the beginning of the study for baseline and a second time at the end of the study, so it may have been more beneficial to measure serially; 3) patient recruitment was through a few different healthcare centers, which may have introduced spectrum bias and affected study results; 4) no sample size calculation was done, so that the number of eligible patients for the study (n = 43) may have been too small to accurately assess the association between predictor (i.e., elevated sEDN and positive IgE for HDM) and outcome (significant improvement in ACD, sEDN and rescue medication following treatment).
Search related documents:
Co phrase search for related documents- sample size calculation and significant improvement: 1, 2
- sample size calculation and study end: 1, 2
- sample size calculation and study result: 1
- second time and significant improvement: 1, 2, 3
- second time and study end: 1, 2, 3
- second time and study result: 1
- second time and treatment follow: 1
- secondary outcome and significant improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- secondary outcome and study eligible patient: 1
- secondary outcome and study end: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- secondary outcome and Study limitation: 1, 2
- secondary outcome and study result: 1, 2
- secondary outcome and treatment follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- sEDN level and study end: 1
- significant improvement and study end: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- significant improvement and study result: 1, 2, 3, 4
- significant improvement and treatment follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- study end and treatment follow: 1, 2, 3, 4, 5, 6, 7, 8, 9
- study result and treatment follow: 1
Co phrase search for related documents, hyperlinks ordered by date